U.S. market Closed. Opens in 11 hours 33 minutes

CNTA | Centessa Pharmaceuticals plc Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue6.88MN/AN/AN/AN/A
Cost of Revenue813.14K130.92K33.99KN/AN/A
Gross Profit6.07M-130.92K-33.99KN/AN/A
Operating Expenses178.01M210.28M139.28M10.44M5.05M
Selling, General & Admin53.13M55.20M42.97M1.14M790.00K
Research & Development124.89M155.08M96.31M9.30M4.26M
Other Operating Expenses-5.43M2.34MN/A155.00K105.00K
Operating Income-171.95M-212.26M-139.31M-10.44M-5.05M
Other Expenses / Income-4.88M-4.69M-242.43M-223.00K-8.00K
Before Tax Income-176.82M-216.95M-381.74M-10.66M-5.06M
Income Tax Expenses-25.15M-747.00K113.99K378.00K223.00K
Net Income-151.67M-216.21M-381.85M-11.04M-5.28M
Interest Expenses9.91M7.03M2.55M378.00K118.00K
Basic Shares Outstanding96.18M93.40M89.99M142.06M70.89M
Diluted Shares Outstanding96.18M93.40M89.99M142.06M70.89M
EBITDA-171.13M-207.94M-139.28M-10.29M-4.94M
EBITDA Margin-2,487.57%0.00%0.00%0.00%0.00%
EBIT-166.92M-209.92M-379.19M-10.29M-4.94M
EBIT Margin-2,426.28%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙